Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sintilimab,Pemetrexed,Platinum
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Advisory Committee Votes to Recommend Additional Data for Sintilimab Submission
Details : Tyvyt (sintilimab),is a novel PD-1 inhibitor, is under review for the first-line treatment of people with non-squamous non-small cell lung cancer based on the ORIENT-11 trial conducted exclusively in China.
Product Name : Tyvyt
Product Type : Antibody
Upfront Cash : Inapplicable
November 02, 2022
Lead Product(s) : Sintilimab,Pemetrexed,Platinum
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sintilimab,Pemetrexed,Platinum
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lilly Statement on Sintilimab Oncologic Drugs Advisory Committee (ODAC) Meeting
Details : TYVYT (sintilimab injection), is an immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-L1 pathway, and reactivates T-cells to kill cancer cells.
Product Name : Tyvyt
Product Type : Antibody
Upfront Cash : Inapplicable
October 02, 2022
Lead Product(s) : Sintilimab,Pemetrexed,Platinum
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sintilimab,Pemetrexed,Platinum
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tyvyt (sintilimab), an investigational PD-1 inhibitor a type of immunoglobulin G4 monoclonal antibody, binds to PD-1 molecules on surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.
Product Name : Tyvyt
Product Type : Antibody
Upfront Cash : Inapplicable
March 24, 2022
Lead Product(s) : Sintilimab,Pemetrexed,Platinum
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pembrolizumab,Fluoropyrimidine,Platinum
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.
Product Name : Keytruda
Product Type : Antibody
Upfront Cash : Inapplicable
May 24, 2021
Lead Product(s) : Pembrolizumab,Fluoropyrimidine,Platinum
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sintilimab,Pemetrexed,Platinum
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A total of 397 patients were enrolled and randomized 2:1 to receive either sintilimab 200mg or placebo in combination with pemetrexed and platinum chemotherapy every 3 weeks for up to four cycles, followed by either sintilimab or placebo plus pemetrexed ...
Product Name : Tyvyt
Product Type : Antibody
Upfront Cash : Inapplicable
May 18, 2021
Lead Product(s) : Sintilimab,Pemetrexed,Platinum
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pembrolizumab,Fluoropyrimidine,Platinum
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Merck Provides Update on KEYTRUDA® (Pembrolizumab) Indication in Third-Line Gastric Cancer in the US
Details : KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Product Name : Keytruda
Product Type : Antibody
Upfront Cash : Inapplicable
January 07, 2021
Lead Product(s) : Pembrolizumab,Fluoropyrimidine,Platinum
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sintilimab,Gemcitabine,Platinum
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application for TYVYT® (sintilimab injection) in combination with Gemzar® (gemcitabine) and platinum as first-line therapy in squamous non-small cell lung c...
Product Name : Tyvyt
Product Type : Antibody
Upfront Cash : Inapplicable
December 08, 2020
Lead Product(s) : Sintilimab,Gemcitabine,Platinum
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sintilimab,Pemetrexed,Platinum
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Based on the interim analysis, sintilimab in combination with ALIMTA and platinum demonstrated a statistically significant improvement in PFS compared with placebo with ALIMTA and platinum combo.
Product Name : Tyvyt
Product Type : Antibody
Upfront Cash : Inapplicable
December 01, 2020
Lead Product(s) : Sintilimab,Pemetrexed,Platinum
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sintilimab,Pemetrexed,Platinum
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The ORIENT-11 primary clinical results were released during the IASLC World Conference on Lung Cancer (WCLC) 2020 Virtual Presidential Symposium as an oral presentation and simultaneously published by the Journal of Thoracic Oncology.
Product Name : Tyvyt
Product Type : Antibody
Upfront Cash : Inapplicable
September 21, 2020
Lead Product(s) : Sintilimab,Pemetrexed,Platinum
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sintilimab,Gemcitabine,Platinum
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ORIENT-12 is the first randomized, double-blind, Phase 3 clinical trial evaluating TYVYT® or placebo in combination with GEMZAR® and platinum chemotherapy as first-line treatment for advanced or metastatic squamous non-small cell lung cancer.
Product Name : Tyvyt
Product Type : Antibody
Upfront Cash : Inapplicable
September 21, 2020
Lead Product(s) : Sintilimab,Gemcitabine,Platinum
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable